October 25, 2017 10:21 AM EDTUpdated 10:44 AM
News Briefing

PDU­FA date past, PTC still hasn’t said what the FDA’s ver­dict was; BioIn­vent search­ing for a new CEO

John Carroll

Editor & Founder

→ So what’s hap­pen­ing with PTC Ther­a­peu­tics? The PDU­FA date for its Duchenne mus­cu­lar dy­s­tro­phy drug ataluren came and went yes­ter­day with­out a peep from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times